337
Views
0
CrossRef citations to date
0
Altmetric
Review

What is the link between vitamin D and tuberculosis?

, MBChB, MMed (Specialist Physician) , , MBChB, MMed & , MBChB, MMed, PhD
Pages 192-196 | Received 09 Oct 2012, Accepted 04 Feb 2013, Published online: 15 Jul 2015

References

  • Global tuberculosis control. Geneva: World Health Organisation; 2011.
  • Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis. 2010;50(10):1377–1386.
  • Zhang R, Naughton D. Vitamin D in health and disease: Current perspectives. Nutr J. 2010;9:65.
  • Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357.
  • Kelechi E, Aileen C. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008;37(1):113–119.
  • Davies P. A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis. Tubercle. 1985;66(4):301–30 6.
  • Davies P. A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis. Tubercle. 1985;66(4):301–306.
  • Anandaiah A, Sinha S, Sharma S, et-al. Vitamin D increases apoptosis in macrophages exposed to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2009;179:A5917.
  • Veldman C, Cantorna M, DeLuca H. Expression of 1, 25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334–338.
  • Hansdottir S, Mon ick M. Vitam in D effects on lung immunity and respiratory diseases.Vitam Horm. 201186: 217–237.
  • Houben E, Nguyen L, Pieters J. Interaction of pathogenic mycobacteria with the host immune system. Curr Opin Microbiol. 2006;9(1):76–85.
  • Liu P, Stenger S, Li H, et-al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–1773.
  • Liu P, Stenger S, Tang D. Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J lmmunol. 2007;179(4):2060–2063.
  • Rivas-Santiago B, Hernandez-Pando R, Carranza C, et al. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect lmmun. 2008;76(3):935–941.
  • Hmama Z, Sendide K, Talal A, et al. Quantitative analysis of phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue by an 1alpha, 25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J Cell Sci. 2004;117(F't 10):2131–2140.
  • Abe E, Shiina Y, Miyaura C, et al. Activation and fusion induced by 1 alpha, 25-dihydroxyvitamin D3 and their relation in alveolar macrophages. Proc Natl Acad Sci USA. 1984;81(2):7112–7116.
  • Hewison M. Vitamin D and innate and adaptive immunity. Vitam Horm. 2011;86:23–62.
  • Rockett K, Brookes R, Udalova 1, et al. 1, 25-dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect lmmun. 1998;66(11):5314–5321.
  • Luong K, Nguyen L. Impact of Vitamin D in the treatment of tuberculosis. Am J Med Sci. 2011341(6):493–498.
  • Elkington P, Nuttall R, Boyle J, et al. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med. 2005;172(12):1596–604.
  • Chang J, Wysocki A, Tchou-Wong K, et al. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax. 1996;51(3):306–311.
  • Coussens A, Timms P, Boucher B, et al. 1alpha, 25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology. 2009;127(4):539–548.
  • Anand S, Selvaraj P. Effect of 1, 25 dihydroxyvitamin D3 on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1in pulmonary tuberculosis. Clin lmmunol. 2009;133(1):126–131.
  • Charpy J. Aspects of vitamin and functional substance therapy in dermatology. Bull Med. 1950;64(24):555–559.
  • Dowling G, Prosser E. Treatment of lupus vulgaris with calciferol. Lancet. 1946;1(6408):919–922.
  • Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007;176(2):208–213.
  • Morcos M, Gabr A, Samuel S, et al. Vitam in D administration to tuberculous children and its value. Boll Chim Farm. 1998;137(5):157–164.
  • Nursyam E, Amin Z, Rumende C. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med lndones. 2006;38(1):3–5.
  • Martineau A, Timms P, Bothamley G, et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377(9761):242–250.
  • Yende S, D'Angelo G, Kellum J, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177(11):1242–1247.
  • Siempos 1, Vardakas K, Kopterides P, Falagas M. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008;62(4):661–668.
  • Coussens A, Wilkinson R, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci. 2012;109(38):15449–15454.
  • Yamshchikov A, Oladele A, Leonard-Jr M, et al. Vitam in D as adjunctive therapy in refractory pulmonary tuberculosis: a case report. South Med J. 2009;102(6):649–652.
  • Range N, Changalucha J, Krarup H, et al.The effect of multivitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza, Tanzania. Br J Nut. 2006;95(4):762–770.
  • Weise C, Gomes V, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Grit Care Med. 2009;179(9):843–850.
  • Gibney K, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis. 2008;46(3):443–446.
  • Davies P, Brown R, Woodhead J. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax. 1985;40(3):187–190.
  • Davies P, Church H, Brown R, Woodhead J. Raised serum calcium in tuberculosis patients in Africa. Eur J Respir Dis. 1987;71(5):341–344.
  • Grange J, Davies P, Brown R, et al. A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis. Tubercle. 1985;66(3):187–191.
  • Davies P, Church H, Bovornkitti S, et al. Altered vitamin D homeostasis in tuberculosis. Int Med Thailand. 1988;4:45–47.
  • Sasidharan P, Rajeev E, Vijayakumari V. Tuberculosis and vitamin D deficiency. J Assoc Physicians India. 2002;50:554–558.
  • Ho-Pham L, Nguyen D, Nguyen T, et al. Association between vitamin D insufficiency and tuberculosis in a vietnamese population. BMC Infect Dis. 2010;10:306.
  • Wilkinson R, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000;355(9204):618–621.
  • Arabi A, El-Rassi R, El-Hajj-Fuleihan G. Hypovitaminosis D in developing countries: prevalence, risk factors and outcomes. Nat Rev Endocrinol. 2010;6(10):550–561.
  • Nansera D, Graziano F, Friedman D, et al. Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. Int J Tuberc Lung Dis. 2011;15(11):1522–1527.
  • Friis H, Range N, Pedersen M, et al. Hypovitaminosis D is common among pulmonary tuberculosis patients in Tanzania but is not explained by the acute phase response. J Nutr. 2008;138(12):2474–2480.
  • Wejse C, Olesen R, Rabna P, et al. Serum 25-hydroxyvitamin Din a West African population of tuberculosis patients and unmatched healthy controls.Am J Clin Nut. 2007;86(5):1376–1383.
  • Banda R, Mhemedi B, Allain T. Prevalence of vitamin D deficiency in adult tuberculosis patients at a central hospital in Malawi. Int J Tuberc Lung Dis. 201115(3):408–410.
  • Martineau A, Nhamoyebonded S, Onic T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci. 2011;108(47):19013–10917.
  • Bellamy R. Evidence of gene-environment interaction in development of tuberculosis. Lancet. 2000;355(9204):588–589.
  • Ellamy R, Ruwende C, Corrah T, et-al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the Vitamin D receptor gene. J Infect Dis. 1999;179(3):721–724.
  • Wilbur A, Kubatko L, Hurtado A, et al. Vitamin D receptor gene polymorphisms and susceptibility M. tuberculosis in native Paraguayans. Tu bercu losis (Ed in b). 2007;87(4):329–337.
  • Selvaraj P, Narayanan P, Reetha A. Association of vitamin D receptor genotypes with the susceptibility to pulmonary tuberculosis in female patients and resistance in female contacts. Indian J Med Res. 2000;111:172–179.
  • Roth D, Soto G, Arenas F, et al. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J Infect Dis. 2004;190(5):920–927.
  • Dean D, Schwartz Z, Schmitz J, et al. Vitamin D regulation of metalloproteinase activity in matrix vesicles. Connect Tissue Res. 1996;35(1-4):331–336.
  • Babb C, van der Merwe L, Beyers N, et al. Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis patients. Tuberculosis (Edinb). 2007;87(4):295–302.
  • Gao L, Tao Y, Zhang L, Jin Q. Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14(1):15–23.